Biocon Q1 Core Operations Shine

  Published 11 months ago

Biocon’s Q1 FY26 saw core EBITDA grow 11% YoY, with strong biosimilars and CRDMO growth offsetting one-time gains.

  • Biosimilars revenue jumped 18% YoY to Rs 2,458 crore, fueled by strong demand and new product launches globally.
  • CRDMO business grew 11% in revenue and 19% in EBITDA, driven by pilot programs converting into long-term contracts.
  • Operating revenue rose 15% YoY to Rs 3,942 crore, reflecting broad-based growth across biosimilars, generics, and research services.

You might like these

Rapido Enters Food Delivery to Challenge Swiggy, Zomato

India’s State Refiners Shift from Russian Oil

India's PMI Hits 14-Month High in June 2024

Go Digit Gains on Upbeat Q1 and PT Hikes

Asian Markets Rally on China Rate Cut

Dreamfolks Stock Plummets Amid Airport Operator Rivalry

SSFL Faces Profitability and Asset Quality Challenges

News that matters the most ⚡